Black Diamond Therapeutics (BDTX) vs Kazia Therapeutics (KZIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Black Diamond Therapeutics (BDTX) over the past year, gaining 23.2% versus a loss of 54.6%. Over five years, BDTX leads with a -77.9% price change compared with -98.3% for KZIA. Black Diamond Therapeutics is the larger company by market cap ($103.7 million vs $100.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | KZIA |
|---|---|---|
| Share price | $1.81 | $8.82 |
| Market cap | $103.72M | $100.79M |
| 1-day change | -1.09% | -5.06% |
| YTD return | -25.51% | +28.01% |
| 1-year return | -54.64% | +23.18% |
| 5-year return | -77.87% | -98.32% |
| EPS (TTM) | $-0.75 | $-6.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.94 | $17.40 |
| 52-week low | $1.60 | $4.86 |
| Distance from 52-week high | -63.36% | -49.31% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +452.49% | +220.41% |
| Average volume | 624.32K | 262.41K |
| Shares outstanding | 57.30M | 11.43M |
| Employees | 21 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed BDTX by 77.8 percentage points over the past year.
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
BDTX vs KZIA FAQ
Which is bigger, Black Diamond Therapeutics or Kazia Therapeutics?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $103.72M compared with $100.79M for Kazia Therapeutics (KZIA).
Which stock has performed better over the past year, BDTX or KZIA?
KZIA returned +23.18% over the past 12 months, compared with -54.64% for BDTX (price return, excluding dividends). Past performance does not predict future results.
Are Black Diamond Therapeutics and Kazia Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Black Diamond Therapeutics and Biotechnology: Pharmaceutical Preparations for Kazia Therapeutics.